No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:08:53.429Z. Latest historical point 2026-03-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Spruce Biosciences, Inc. (SPRB) stock was $42.79 as of Oct 6, 2026, 4:00 PM EDT, down 5.80% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -65.3% · 3-year avg -33.7%/yr · 5-year avg -36.2%/yr
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions.
Biotechnology · South San Francisco, CA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-5.68
Revenue Est.
$50.00M
Last Quarter Results
EPS
$-6.68
vs Estimate
$-6.12
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SPRB | $117.76M | $42.78 | -5.80% | -65.29% | -36.23% | N/A | N/A |
| 2TNYA | $118.59M | $0.55 | -3.12% | -65.00% | -52.81% | N/A | vs SPRB |
| 3MXCT | $116.76M | $1.09 | +0.93% | -36.70% | -37.32% | N/A | vs SPRB |
| 4LENZ | $118.83M | $3.79 | +5.57% | -92.54% | -35.49% | N/A | vs SPRB |
| 5CBUS | $119.84M | $1.57 | -6.55% | +16.58% | -59.70% | N/A | vs SPRB |
| 6FHTX | $115.67M | $1.97 | -1.50% | -56.72% | -31.87% | N/A | vs SPRB |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$148.00
+245.9% upside
Low
$104.00
Current
$42.78
High
$230.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-6.82 | $-5.68 | $-5.05 | 5 |
| Quarter ending Dec 2026 | $-6.66 | $-5.34 | $-4.22 | 5 |
| Quarter ending Mar 2027 | $-5.84 | $-5.84 | $-5.84 | 3 |
| Quarter ending Jun 2027 | $-5.93 | $-5.93 | $-5.93 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-28.89 | $-25.74 | $-23.52 | 6 |
| FY 2027 | $-10.92 | $0.90 | $9.44 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $50.00M | $50.00M | $50.00M | 1 |
| Quarter ending Dec 2026 | $3.77M | $3.77M | $3.77M | 1 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $15.74M | $53.75M | $135.20M | 4 |
| FY 2027 | $4.93M | $78.70M | $208.95M | 7 |
